Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed....
Gespeichert in:
| Veröffentlicht in: | Ophthalmologica (Basel) 2017-01, Vol.237 (3), p.123-127 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 3 |
| container_start_page | 123 |
| container_title | Ophthalmologica (Basel) |
| container_volume | 237 |
| creator | Nakai, Shunichiro Honda, Shigeru Miki, Akiko Matsumiya, Wataru Nakamura, Makoto |
| description | Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR. Results: The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV. Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV. |
| doi_str_mv | 10.1159/000455273 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1880079712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1880079712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-d7169296801c44c54ce6d95cb05203238f2fadb42b56132d1446d05ebdcbea663</originalsourceid><addsrcrecordid>eNpt0Mtu1DAUBmALgei0ZcEeIUtsYBE4vuWyrEalrdRqKlrYRr5lYkjiYDutpg_Ac5Mqw6xY-Uj-zn-kH6G3BD4TIqovAMCFoAV7gVaEU5YBzYuXaAXAIGOFEEfoOMafADOuyGt0REtGeVmUK_Rn7ftRBhf9gH2DU2sxodmNH1KLN1PSvrfx-eNqSEE-uBSs7PA3OTjlnqZeKqxserR2wPePHp8NW-e3QY6t0_huUmk3Ltu3vtuN3pl5d936sEw_ZNRT50eZ2t0petXILto3-_cEff96fr--zK43F1frs-tMc4CUmYLkFa3yEojmXAuubW4qoRUICoyysqGNNIpTJXLCqCGc5waEVUYrK_OcnaCPS-4Y_O_JxlT3LmrbdXKwfoo1KUuAoioInemnhergYwy2qcfgehl2NYH6ufb6UPts3-9jJ9Vbc5D_ep7BhwX8kmFrwwFsbi-XiHo0zaze_Vftr_wFUn-TZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1880079712</pqid></control><display><type>article</type><title>Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy</title><source>Karger Journals</source><source>MEDLINE</source><creator>Nakai, Shunichiro ; Honda, Shigeru ; Miki, Akiko ; Matsumiya, Wataru ; Nakamura, Makoto</creator><creatorcontrib>Nakai, Shunichiro ; Honda, Shigeru ; Miki, Akiko ; Matsumiya, Wataru ; Nakamura, Makoto</creatorcontrib><description>Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR. Results: The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV. Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV.</description><identifier>ISSN: 0030-3755</identifier><identifier>EISSN: 1423-0267</identifier><identifier>DOI: 10.1159/000455273</identifier><identifier>PMID: 28324878</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Angiogenesis Inhibitors - administration & dosage ; Choroid - blood supply ; Choroid Diseases - diagnosis ; Choroid Diseases - drug therapy ; Female ; Fluorescein Angiography - methods ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Male ; Original Paper ; Polyps - diagnosis ; Polyps - drug therapy ; Ranibizumab - administration & dosage ; Retrospective Studies ; Time Factors ; Tomography, Optical Coherence - methods ; Treatment Outcome</subject><ispartof>Ophthalmologica (Basel), 2017-01, Vol.237 (3), p.123-127</ispartof><rights>2017 S. Karger AG, Basel</rights><rights>2017 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-d7169296801c44c54ce6d95cb05203238f2fadb42b56132d1446d05ebdcbea663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28324878$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakai, Shunichiro</creatorcontrib><creatorcontrib>Honda, Shigeru</creatorcontrib><creatorcontrib>Miki, Akiko</creatorcontrib><creatorcontrib>Matsumiya, Wataru</creatorcontrib><creatorcontrib>Nakamura, Makoto</creatorcontrib><title>Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy</title><title>Ophthalmologica (Basel)</title><addtitle>Ophthalmologica</addtitle><description>Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR. Results: The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV. Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV.</description><subject>Aged</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Choroid - blood supply</subject><subject>Choroid Diseases - diagnosis</subject><subject>Choroid Diseases - drug therapy</subject><subject>Female</subject><subject>Fluorescein Angiography - methods</subject><subject>Follow-Up Studies</subject><subject>Fundus Oculi</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Original Paper</subject><subject>Polyps - diagnosis</subject><subject>Polyps - drug therapy</subject><subject>Ranibizumab - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Tomography, Optical Coherence - methods</subject><subject>Treatment Outcome</subject><issn>0030-3755</issn><issn>1423-0267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0Mtu1DAUBmALgei0ZcEeIUtsYBE4vuWyrEalrdRqKlrYRr5lYkjiYDutpg_Ac5Mqw6xY-Uj-zn-kH6G3BD4TIqovAMCFoAV7gVaEU5YBzYuXaAXAIGOFEEfoOMafADOuyGt0REtGeVmUK_Rn7ftRBhf9gH2DU2sxodmNH1KLN1PSvrfx-eNqSEE-uBSs7PA3OTjlnqZeKqxserR2wPePHp8NW-e3QY6t0_huUmk3Ltu3vtuN3pl5d936sEw_ZNRT50eZ2t0petXILto3-_cEff96fr--zK43F1frs-tMc4CUmYLkFa3yEojmXAuubW4qoRUICoyysqGNNIpTJXLCqCGc5waEVUYrK_OcnaCPS-4Y_O_JxlT3LmrbdXKwfoo1KUuAoioInemnhergYwy2qcfgehl2NYH6ufb6UPts3-9jJ9Vbc5D_ep7BhwX8kmFrwwFsbi-XiHo0zaze_Vftr_wFUn-TZQ</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Nakai, Shunichiro</creator><creator>Honda, Shigeru</creator><creator>Miki, Akiko</creator><creator>Matsumiya, Wataru</creator><creator>Nakamura, Makoto</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy</title><author>Nakai, Shunichiro ; Honda, Shigeru ; Miki, Akiko ; Matsumiya, Wataru ; Nakamura, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-d7169296801c44c54ce6d95cb05203238f2fadb42b56132d1446d05ebdcbea663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Choroid - blood supply</topic><topic>Choroid Diseases - diagnosis</topic><topic>Choroid Diseases - drug therapy</topic><topic>Female</topic><topic>Fluorescein Angiography - methods</topic><topic>Follow-Up Studies</topic><topic>Fundus Oculi</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Original Paper</topic><topic>Polyps - diagnosis</topic><topic>Polyps - drug therapy</topic><topic>Ranibizumab - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Tomography, Optical Coherence - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakai, Shunichiro</creatorcontrib><creatorcontrib>Honda, Shigeru</creatorcontrib><creatorcontrib>Miki, Akiko</creatorcontrib><creatorcontrib>Matsumiya, Wataru</creatorcontrib><creatorcontrib>Nakamura, Makoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmologica (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakai, Shunichiro</au><au>Honda, Shigeru</au><au>Miki, Akiko</au><au>Matsumiya, Wataru</au><au>Nakamura, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy</atitle><jtitle>Ophthalmologica (Basel)</jtitle><addtitle>Ophthalmologica</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>237</volume><issue>3</issue><spage>123</spage><epage>127</epage><pages>123-127</pages><issn>0030-3755</issn><eissn>1423-0267</eissn><abstract>Background: To compare the 12-month outcomes of intravitreal ranibizumab (IVR) between two angiographic subtypes of polypoidal choroidal vasculopathy (PCV). Methods: This is a retrospective cohort study of 38 treatment-naïve PCV cases. Three consecutive IVR and retreatments as needed were performed. Subsequently, the PCV cases were classified into two phenotypes (18 type 1 and 20 type 2) according to the status of branching vascular network. The best-corrected visual acuity (BCVA) was evaluated in each PCV subtype up to 12 months after the initial IVR. Results: The mean BCVA was significantly improved from baseline in type 1 PCV while not in type 2 PCV. In type 2 PCV, 3 cases showed severe visual loss after 6 months from the initial IVR. The mean retreatment number was 1.9 ± 1.7 in type 1 PCV and 1.2 ± 1.3 in type 2 PCV. Conclusions: The outcomes of IVR may be different between two angiographic subtypes of PCV.</abstract><cop>Basel, Switzerland</cop><pmid>28324878</pmid><doi>10.1159/000455273</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-3755 |
| ispartof | Ophthalmologica (Basel), 2017-01, Vol.237 (3), p.123-127 |
| issn | 0030-3755 1423-0267 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1880079712 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Angiogenesis Inhibitors - administration & dosage Choroid - blood supply Choroid Diseases - diagnosis Choroid Diseases - drug therapy Female Fluorescein Angiography - methods Follow-Up Studies Fundus Oculi Humans Intravitreal Injections Male Original Paper Polyps - diagnosis Polyps - drug therapy Ranibizumab - administration & dosage Retrospective Studies Time Factors Tomography, Optical Coherence - methods Treatment Outcome |
| title | Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A17%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%2012-Month%20Outcomes%20of%20Intravitreal%20Ranibizumab%20between%20Two%20Angiographic%20Subtypes%20of%20Polypoidal%20Choroidal%20Vasculopathy&rft.jtitle=Ophthalmologica%20(Basel)&rft.au=Nakai,%20Shunichiro&rft.date=2017-01-01&rft.volume=237&rft.issue=3&rft.spage=123&rft.epage=127&rft.pages=123-127&rft.issn=0030-3755&rft.eissn=1423-0267&rft_id=info:doi/10.1159/000455273&rft_dat=%3Cproquest_cross%3E1880079712%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1880079712&rft_id=info:pmid/28324878&rfr_iscdi=true |